Evogene shareholders approve four 2026 proposals
Evogene Ltd. confirms approval of key AGM proposals and sets its post-meeting board composition, with the disclosure incorporated into existing F-3 and S-8 registrations.
Rhea-AI Filing Summary
Evogene Ltd. (EVGN) reports that it held its annual general meeting of shareholders on September 4, 2026, with a quorum present and shareholder voting conducted on proposals previously described in its July 31, 2026 proxy materials. Proposals 1(a) and 2–4 were approved by the requisite shareholder vote.
Effective at the end of the meeting, Evogene’s board of directors consists of Nir Nimrodi, Adrian Percy, Leon Y. Recanati, Dan Falk, Yael Margolin, Yoshinori Oikawa, and Ofer Haviv, who also serves as CEO and President. The information in this report is incorporated by reference into Evogene’s existing Form F-3 and Form S-8 registration statements.
Positive
- None.
Negative
- None.
Key Figures
Annual general meeting date: September 4, 2026
Number of approved proposals: 4 proposals (1(a) and 2–4)
Number of board members after meeting: 7 directors
3 metrics
Annual general meeting date
September 4, 2026
Date Evogene held its annual general meeting of shareholders
Number of approved proposals
4 proposals (1(a) and 2–4)
Proposals approved by requisite shareholder vote at the meeting
Number of board members after meeting
7 directors
Size of Evogene’s board effective at the end of the meeting
Key Terms
Report of Foreign Private Issuer, Form 20-F, Form F-3, Form S-8, +1 more
5 terms
Report of Foreign Private Issuer regulatory
"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A report of a foreign private issuer is a formal filing that a non‑U.S. company makes to U.S. regulators to share important business, financial, or governance information with American investors. Think of it as a regular update or press packet that keeps investors informed about events that could change a company’s value—like earnings, management changes, contracts, or regulatory developments—so investors can make timely, informed decisions.
Form 20-F regulatory
"whether the registrant files or will file annual reports under cover of Form 20-F"
Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.
Form F-3 regulatory
"incorporated by reference in the registration statements on Form F-3"
Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.
Form S-8 regulatory
"incorporated by reference in the registration statements on ... Form S-8"
A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.
registration statements regulatory
"incorporated by reference in the registration statements on Form F-3"
Registration statements are detailed documents companies file with securities regulators when they plan to offer shares or other securities to the public. They act like a recipe and instruction manual, listing a company’s business, finances, management, risks and how the offering will work, so investors can judge value and potential downsides. For investors, these filings provide the official, legally required facts needed to make informed decisions and spot warning signs.
FAQ
What did Evogene Ltd. (EVGN) announce in its September 2026 Form 6-K?
Evogene announced that its annual general meeting of shareholders was held on September 4, 2026, that a quorum was present, and that shareholder votes were taken on proposals previously described in its July 31, 2026 proxy materials, with several proposals approved.
Who are the current board members of Evogene Ltd. (EVGN) after the 2026 AGM?
Effective at the end of the meeting, Evogene’s board consists of Nir Nimrodi, Adrian Percy, Leon Y. Recanati, Dan Falk, Yael Margolin, Yoshinori Oikawa, and Ofer Haviv, who also serves as CEO and President.
Did Evogene (EVGN) confirm quorum at the September 4, 2026 annual general meeting?
Yes. Evogene states that a quorum was present at the annual general meeting of shareholders held on September 4, 2026, allowing the company to conduct official shareholder business and vote on the proposals.
How does this Evogene Ltd. (EVGN) 6-K affect its existing registration statements?
Evogene states that the contents of this Form 6-K are incorporated by reference into its registration statements on Form F-3 (File Nos. 333-277565 and 333-294650) and Form S-8 (File Nos. 333-193788, 333-201443, 333-203856, 333-259215, 333-286197 and 333-294648).
Where was Evogene Ltd. (EVGN)’s 2026 annual general meeting held?
Evogene held the annual general meeting of shareholders at its offices at 13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel, on September 4, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
